A Study of AT-02 in Subjects With Systemic Amyloidosis.

NCT05951049

Status	RECRUITING
Phase	Phase 2
Sponsor	Attralus, Inc.
Enrollment	120 participants

Key Eligibility Criteria

Inclusion (22)

- Subject understands the study procedures and can give signed informed consent.
- Subject is willing and able to comply with this protocol and will be available for the entire duration of the study.
- Has a confirmed diagnosis of AL amyloidosis and meets the criteria below:
- Histologic confirmation with a biopsy containing deposits of apple-green birefringent, Congophilic material or other amyloid staining (i.e., thioflavin T or sulfated alcian blue) with confirmatory immunohistochemistry or mass spectrometry, AND
- May be receiving maintenance daratumumab and must have achieved and maintained a hematologic very good partial response (VGPR) or complete response (CR), have completed chemotherapy therapy (ie, melphalan, bortezomib, thalidomide, lenalidomide, or cyclophosphamide) and be at least 6 months from first hematologic response (CR or VGPR), AND

... and 17 more (see full listing online)

Exclusion (26)

- Receiving hemodialysis or peritoneal dialysis.
- Myocardial infarction within 3 months of Screening.
- New York Heart Association Class IV heart failure.
- Kidney disease not caused by AL amyloidosis.
- Respiratory insufficiency requiring oxygen therapy.

... and 21 more (see full listing online)

Locations (4 total)

Kansas City, Kansas City, Kansas, United States
Cleveland Clinic, Cleveland, Ohio, United States
OHSU (Oregon Health & Science University), Portland, Oregon, United States
... and 1 more locations